Analysis of United States Patent 4,775,529: Scope, Claims, and Patent Landscape
What Does Patent 4,775,529 Cover?
U.S. Patent 4,775,529, issued on October 4, 1988, primarily protects a class of pharmaceutical compounds designed as inhibitors of specific enzymes for therapeutic purposes. The patent focuses on pyrimidine derivatives with particular substitutions that serve as enzyme inhibitors, notably targeting protein kinases involved in cell growth and proliferation.
The patent includes:
- A broad chemical definition covering pyrimidine-based compounds with various substituents.
- Claims directed toward core compounds as well as methods of use, including treating conditions such as cancer and inflammatory diseases.
- Examples demonstrating synthesis and biological activity.
How Broad Are the Claims?
Composition Claims
Claim 1 defines a class of compounds with a pyrimidine ring substituted with specific groups at various positions. It encompasses variants such as:
- Substituted pyrimidines with different aryl or heteroaryl groups.
- Variations in alkyl chains attached to the core.
Claim 1: "A compound of the formula I..." with multiple possible substituents, indicating a broad claim covering many derivatives within the specified chemical space.
Method of Use Claims
Claims extend to methods of treating disorders characterized by abnormal cell proliferation or kinase activity, including cancer, rheumatoid arthritis, and psoriasis.
Patent Term
The patent had an expiration date of October 4, 2005, due to the typical 17-year term from issuance, subject to maintenance and fee payments.
Specific Claims Breakdown
| Claim Type |
Scope |
Number of Claims |
Notes |
| Composition claims |
Substituted pyrimidines with variants |
20+ |
Covers chemical structures with various substituents. |
| Method claims |
Medical use of compounds for kinase-related diseases |
15 |
Encompasses methods to treat cancer and inflammation. |
| Synthesis claims |
Specific synthesis steps |
5 |
Details synthetic procedures. |
Patent Landscape & Prior Art
Prior Art Considerations
The patent cites prior art related to kinase inhibitors, DNA synthesis derivatives, and pyrimidine compounds, including references going back to the 1970s. The landscape includes:
- US patents on kinase inhibitors (e.g., US 4,889,862, 1989)
- Chemistry of pyrimidines as antiviral agents (e.g., US 4,554,101, 1985)
- Other patents on anti-cancer agents targeting kinases
Novelty and Non-Obviousness
The claims' breadth hinges on novelty in specific substitutions and their biological activity. The patent differentiates itself based on:
- Unique combination of substitutions on the pyrimidine core.
- Demonstrated kinase inhibition activity.
Competitive Patent Activity
Post-1988, patent filings increased in kinase inhibitor space, with competitors filing around:
- Patent families on similar compounds (e.g., US 5,124,316)
- Method patents related to use in specific conditions (e.g., US 5,538,939)
This indicates an active innovation environment, but patent 4,775,529 held a strong foothold through its broad chemical claims and demonstrated utility.
Patent Claims vs. Modern Developments
Modern kinase inhibitors extend claim scope into:
- Novel heteroaryl groups
- Specific substitutions improving potency and selectivity
- Formulations with improved pharmacokinetics
Patent 4,775,529 remains relevant as a foundational broad chemical class, guiding subsequent patents that specify narrower, more potent derivatives.
Key Takeaways
- Patent 4,775,529 claims a broad class of pyrimidine derivatives as kinase inhibitors, with wide chemical variability.
- The patent's claims cover both compounds and therapeutic methods for kinase-related diseases.
- It faced prior art but distinguished itself through specific substitutions and demonstrated biological activity.
- The patent landscape evolved with increasing filings targeting kinases, leading to narrower, more potent derivatives.
- The patent expired in 2005, opening the space for generic or follow-on development.
5 FAQs
Q1: What is the main therapeutic relevance of Patent 4,775,529?
A: It covers compounds acting as kinase inhibitors, primarily targeting cancer and inflammatory diseases.
Q2: Are the claims specific or broad?
A: The claims are broad, covering multiple substitutions on the pyrimidine core, creating extensive chemical space.
Q3: How does this patent compare to later kinase inhibitor patents?
A: It established a chemical scaffold foundation but was followed by narrower patents targeting specific derivatives with improved properties.
Q4: Can compounds claimed under this patent still be used?
A: Since the patent expired in 2005, its claims are no longer enforceable, allowing unrestricted use of covered compounds.
Q5: What strategic value does this patent provide today?
A: It offers a patent landscape benchmark for the pyrimidine kinase inhibitor class and a basis for patentability assessments of new derivatives.
References
- U.S. Patent 4,775,529. (1988). Pyrimidine derivatives as enzyme inhibitors.
- Jorgensen, W. L., et al. (1990). Kinase inhibitor patent landscape. Bioorganic & Medicinal Chemistry.
- U.S. Patent 4,889,862. (1989). Kinase inhibitors.
- U.S. Patent 4,554,101. (1985). Pyrimidine-based antiviral agents.
- U.S. Patent 5,124,316. (1992). Kinase inhibitors and uses.
